Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921010 · ClinicalTrials.gov registry record · Phase 4
Benefit of Elevation of HDL-C in Women
A Phase 4 study of Cardiovascular Outcomes, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT01921010: Completed Phase 4 study of Cardiovascular Outcomes, sponsored by Cedars-Sinai Medical Center.
NCT01921010 is a Phase 4 study of Cardiovascular Outcomes that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01921010, a Phase 4 study of Cardiovascular Outcomes, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction accomplished by the addition of niacin to statin medication would improve endothelial function as compared to LDL-C reduction alone in patients with and without coronary artery disease and the combination of low HDL-C/high triglycerides. The combination of lipid lowering therapy would have beneficial effects on markers of inflammation. These benefits would be particularly evident in women.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Niaspan
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2003-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
What the finished NCT01921010 record still lists
NCT01921010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Cardiovascular Outcomes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01921010 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01921010 about?
NCT01921010 is a clinical study titled "Benefit of Elevation of HDL-C in Women". The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction accomplished by the addition of niacin to statin medication would improve endothelial function as compared to LDL-C reduction alone in patients with and without coronary artery disease and the combination of lo...
What is the current status of trial NCT01921010?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2003-06. Estimated completion is 2005-06.
What conditions does trial NCT01921010 study?
This clinical trial studies the following conditions: Cardiovascular Outcomes.
What interventions are being tested in trial NCT01921010?
The interventions under investigation include: Placebo (DRUG), Niaspan (DRUG).
Who is sponsoring clinical trial NCT01921010?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01921010 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01921010's enrollment target sits among peer trials
43 1371st of 2000 higher than 622 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia